Compare Petróleo Brasileiro SA (PBR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs GeneDx Holdings Corp — how do they compare? Petróleo Brasileiro SA trades at $25.34 (market cap $151.94B), while GeneDx Holdings Corp trades at $67.86 (market cap $2.02B). The key difference: Petróleo Brasileiro SA is far larger — about 75.2× GeneDx Holdings Corp's market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and GeneDx Holdings Corp for 19 Days on average.
| PBR | WGS | |
|---|---|---|
Market Cap | $151.94B | $2.02B |
Volume | 30,240,092 | 734,640 |
Sector | Energy | Health |
52-Week High | $24.69 | $167.51 |
52-Week Low | $11.54 | $34.51 |
Typical Hold Time | 25 Days | 19 Days |
Enterprise Value | $212.36B | $2.05B |
Dividend Yield | 6.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $25.41, up 5.92% in 24 hours, reflecting strong momentum. The stock shows robust fundamentals with a P/E of 6.24 and net income margin of 24.52%, supported by recent earnings beats. Technical indicators signal a bullish trend, though RSI levels suggest potential overbought conditions. Positive news includes a new oil discovery off Amapa and a 22-year LNG deal with Cheniere Energy, highlighting growth prospects.
The outlook for PBR is favorable due to solid profitability, expansion projects, and analyst consensus leaning buy. Key risks involve political interference in Brazil, volatile oil prices, and high debt levels. Investors should weigh strong cash flows against geopolitical and commodity cycle exposures for balanced decision-making.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
